Drugs in MeSH Category Insecticides

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Padagis Israel	PERMETHRIN	permethrin	CREAM;TOPICAL	076369-001	Apr 21, 2003	AB	RX	No	Yes
Olta Pharms	LINDANE	lindane	SHAMPOO;TOPICAL	087266-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Galderma Labs Lp	SOOLANTRA	ivermectin	CREAM;TOPICAL	206255-001	Dec 19, 2014	AB	RX	Yes	Yes	10,206,939
Taro	IVERMECTIN	ivermectin	LOTION;TOPICAL	210720-001	May 6, 2020		OTC	No	No
Actavis Labs	PERMETHRIN	permethrin	CREAM;TOPICAL	074806-001	Jan 23, 1998	AB	RX	No	No
Ajanta Pharma Ltd	IVERMECTIN	ivermectin	TABLET;ORAL	218509-001	Apr 7, 2026	AB	RX	No	No

Market dynamics and patent landscape for drugs in NLM MeSH Class: Insecticides

Last updated: April 26, 2026

What counts as “insecticide” drugs in MeSH terms, and why it matters for market mapping

NLM MeSH “Insecticides” is a pharmacologic-chemistry concept used to index agents that kill or control insect populations. For patent and market mapping, the MeSH bucket is best treated as a functional class that spans multiple therapeutic-like “use categories” in practice: agricultural insecticides, vector-control insecticides, and public health control products. This segmentation drives how patents are pursued, how regulatory pathways differ, and how exclusivity monetization occurs.

Two operational realities shape the patent landscape in this bucket

• Entry is formulation- and use-specific. Even when actives are known, exclusivity and patent value often shift to formulations, salts, delivery systems, and protected end-uses (e.g., indoor residual spray vs nets vs crop application).
• Lifecycle strategy is split across chemistry and deployment. Patent families frequently cover the active ingredient plus application modalities, manufacturing processes, and second-generation analogs that address resistance and performance gaps.

How big is the commercial footprint, and what drives demand cycles

Demand in insecticides is anchored to disease-vector epidemiology (vector-control), crop yields and pest pressure (agriculture), and regulatory and procurement cycles (public tenders, registrant renewals). Patent value tends to align with these demand drivers through two common patterns.

Demand drivers that predict post-approval patent monetization

• Resistance pressure. When pest populations develop resistance, the market shifts to next-generation chemistries. This creates “waves” of sales that match new active-ingredient entries and new MoA-based families.
• Procurement timing. Vector-control cycles and public health tenders can concentrate spend into specific years, improving the revenue capture window for brand launches.
• Regulatory renewal friction. Registration re-evaluations and maximum residue limits affect continuity of older actives. Patent families built around risk-reduced dossiers often retain market access longer.

Typical market segmentation for patent analytics

Patent portfolios in insecticides tend to break into three commercial lanes:

• Agricultural insecticides (high-volume, resistance-driven replacement cycles)
• Vector-control insecticides (tender-driven, resistance and operational efficacy)
• Household pest control insecticides (formulation and delivery patents matter; distribution-based competition)

What does the patent landscape look like in practice for insecticides

The patent landscape for insecticides is usually dominated by active-ingredient families plus “secondary” patent layers. The structure is consistent across most mainstream chemistries:

Patent layers commonly seen in insecticides

Patent layer	What it covers	Where it matters for exclusivity
Core active-ingredient claims	Specific chemical structures and stereochemistry	Captures revenue during early life and blocks direct generics
Process/manufacturing	Synthesis routes, intermediates, purification	Extends enforceability when composition claims narrow
Formulation & delivery	Microencapsulation, emulsions, controlled release, spray/impregnation systems	Blocks “equivalent” market entry even when active is known
Resistance management	New analogs and combinations aligned to resistance profiles	Supports new sales waves
Use and method claims	Application parameters and operational methods	Strengthens position in regulated procurement contexts

Patent filing behavior

• Families are frequently cross-jurisdictional (US, EP, JP, CN, and application-specific national filings).
• Second-generation patents often appear before the earliest expiry of core compounds to maintain continuity of exclusivity and enforcement options.
• Combination strategies (where allowed) show up as later-stage families because they require performance and regulatory data.

Which chemical families dominate insecticides, and how that maps to patent strategy

Insecticides broadly cluster by mode of action. These MoA groupings are the main driver of how patent families are built and how quickly markets rotate when resistance emerges.

Major MoA groupings that shape patent cycles

MoA grouping (examples of typical families)	What drives innovation	Common patent monetization focus
Pyrethroids	Resistance and improved knockdown or persistence	Next-gen analogs plus formulation/persistence patents
Neonicotinoids	Target-site resistance management	Active analog expansion; process and seed-treatment formulations
Organophosphates	Toxicology-driven replacements	Lower-risk analogs and process improvements
Carbamates	Resistance and application efficacy	Active chemistry plus application method/formulation
Spinosyns / spinosoids	Resistance management and potency	Analog families and delivery systems
Diamides	Crop targeting and resistance	Active analogs and controlled-release formulations
Phenylpyrazoles (often via fiproles)	Resistance and safety profile	Active and combination formulations
Insect growth regulators (IGRs)	Developmental pathway specificity	Application methods and formulation systems

(These groupings are used here for market-to-patent mapping. The MeSH “Insecticides” tag aggregates across them.)

How regulatory and market access timelines interact with patent expiry

In insecticides, patent expiry does not automatically equal loss of market access because:

• Registration and regulatory data packages can protect incumbents even when patents expire.
• Formulation-specific IP can keep differentiation.
• Commercial agreements and procurement specs can favor established products.

Practical interaction points for exclusivity modeling

• Regulatory lead time can compress effective patent life if active-ingredient development starts late.
• Data exclusivity and registration pathways can delay generic equivalents.
• Resistance events can trigger rapid adoption of new actives, shortening the “generic threat window” for older products even when IP sunsets.

What to watch in the current patent landscape for this MeSH class

Because the MeSH bucket is broad, the most actionable view for investors and R&D leaders is not “the” patent landscape but a set of repeating structures that decide whether patents create enforceable market power.

High-impact signals

• Are core active-ingredient families still in-force in key jurisdictions for the highest-revenue regions?
• Do patents extend into formulation and delivery (sprays, nets, granules, seed treatments) that match procurement specs?
• Are there robust second-generation filings with clear technical differentiation, not only incremental claims?
• Do enforcement strategies hinge on process claims when composition claims narrow?
• Are combination products patented with clear synergy data that regulators accept?

Enforcement leverage patterns

• Stronger positions typically arise when the portfolio covers both composition and deployment modality.
• Portfolios that cover only chemistry can face faster generic entry if formulation and application methods are not protected, depending on registration allowances and procurement acceptance.

How the patent landscape differs by market lane

Agricultural lane

• Innovation concentrates on new active ingredients plus delivery-formulation performance (persistence, systemic action, weather stability).
• Resistance drives demand for new MoA or improved analogs.
• Monetization is often time-phased around crop seasons and regional pest cycles.

Vector-control lane

• Procurement and public health guidelines drive adoption timelines.
• IP value often comes from operational efficacy and deployment platforms (indoor residual spray formulations, impregnated materials, and durability).
• Patent families tied to field performance and reduced resistance spread tend to maintain relevance.

Household lane

• Sales are often distribution-led.
• Patent value often shifts to formulation, safety, and delivery rather than solely the active ingredient.

Where the boundary lies between “insecticide” patents and other pesticide classes

For analysts, the key boundary issue is classification: MeSH “Insecticides” does not include all pest-control agents (e.g., herbicides, fungicides). Patent landscaping should avoid mixing:

• insecticidal agents with
• acaricides (if separately classified), and
• non-insect control chemistries.

This matters for estimating competitive intensity and for identifying true substitutes under real procurement specs.

How businesses should use this landscape for portfolio decisions

For R&D strategy

• Prioritize programs that create defensible differentiation in both chemistry and deployment.
• Build patent families that match the intended operational pathway (spray, treated materials, seed-treatment, controlled release).

For investment underwriting

• Map revenue to active ingredient families and then overlay second-layer patents tied to formulation and use.
• Model the “generic threat” by combining: patent expiry, regulatory pathways, and typical procurement spec behavior.

For partnership and licensing

• Licenses with stronger economics usually include:
  • composition claims for actives,
  • formulation or delivery IP,
  • and at least one enforceable angle on method-of-use or manufacturing process.

Key Takeaways

• MeSH “Insecticides” is a functional bucket that spans multiple MoA families, with market dynamics dominated by resistance pressure, procurement cycles, and regulatory access.
• Patent value is usually layered: core active-ingredient families plus formulation/delivery and manufacturing process patents that match real-world deployment.
• The most actionable patent landscape view for decision-making is lane-specific: agricultural, vector-control, and household markets show different monetization mechanics.
• Underwriting should model exclusivity as a combination of in-force IP, regulatory friction, and procurement/spec acceptance rather than patent expiry alone.

FAQs

1. Does MeSH “Insecticides” correspond to one single drug category for patents?
   No. It aggregates insecticidal agents across multiple chemical MoA families, which produce different patent strategies and competitive substitution patterns.

2. What patent layers most often sustain exclusivity after core active-ingredient patents?
   Formulation and delivery (sprays, impregnated materials, controlled release) and process/manufacturing improvements.

3. Why do resistance events change the patent value of older insecticides?
   Resistance shifts procurement toward new chemistries or analogs, compressing the effective commercial life even if older IP is still enforceable.

4. How should investors model “generic threat” in insecticides?
   Combine patent expiry with formulation-specific protection, regulatory registration timelines, and procurement/spec preferences.

5. Are method-of-use patents common in insecticide portfolios?
   They are used, especially when deployment parameters are central to operational efficacy and can be enforced in the target jurisdiction.

---

References

1. National Library of Medicine. MeSH Browser. “Insecticides.” https://meshb.nlm.nih.gov/ (accessed 2026-04-26).